Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 05 September 2018

Indication(s)

Strimvelis is indicated for the treatment of patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), for whom no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/003854
Orphan designation Yes
Date First Approved 26-05-2016
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Orchard Therapeutics (Netherlands) BV